Dissolving polymer microneedle patches for influenza vaccination

Nature Medicine

Volumn 16, Issue 8, 2010, Pages 915-920

  Sullivan, Sean P ^a   Koutsonanos, Dimitrios G ^b   Del Pilar Martin, Maria ^b   Lee, Jeong Woo ^c   Zarnitsyn, Vladimir ^c   Choi, Seong O ^c   Murthy, Niren ^a   Compans, Richard W ^b   Skountzou, Ioanna ^b   Prausnitz, Mark R ^a,c  

^a Emory University   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Georgia Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INFLUENZA VACCINE; POLYMER;

ANTIGEN PRESENTING CELL; ARTICLE; BIOCOMPATIBILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SOLUBILITY; INFLUENZA; INFLUENZA VACCINATION; LUNG CLEARANCE; MICRONEEDLE; MOUSE; NEEDLE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, CUTANEOUS; ADSORPTION; ANIMALS; ANTIBODY FORMATION; DOSAGE FORMS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; MICE; NEEDLES; ORTHOMYXOVIRIDAE INFECTIONS; POLYMERS; VACCINATION;

MUS; ORTHOMYXOVIRIDAE;

EID: 77955417028     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2182     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Influenza activity\United States and worldwide, 2007-2008 season. MMWR Morb. Mortal. Wkly. Rep. 57, 692-697 (2008).
2. Prausnitz, M.R., Mikszta, J.A., Cormier, M. & Andrianov, A.K. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369-393 (2009).
3. Glenn, G.M. & Kenney, R.T. Mass vaccination: solutions in the skin. Curr. Top. Microbiol. Immunol. 304, 247-268 (2006).
4. Belshe, R.B. et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351, 2286-2294 (2004).
5. Holland, D. et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198, 650-658 (2008).
6. Van Damme, P. et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27, 454-459 (2009).
7. Hickling, J. & Jones, R. Intradermal Delivery of Vaccines: A Review of the Literature and the Potential for Development for Use in Low-and Middle-Income Countries. (Program for Appropriate Technology in Health, Ferney Voltaire, France, 2009).
8. Flynn, P.M. et al. Influence of needle gauge in Mantoux skin testing. Chest 106, 1463-1465 (1994).
9. Prausnitz, M.R. & Langer, R. Transdermal drug delivery. Nat. Biotechnol. 26, 1261-1268 (2008).
10. Gill, H.S., Denson, D.D., Burris, B.A. & Prausnitz, M.R. Effect of microneedle design on pain in human volunteers. Clin. J. Pain 24, 585-594 (2008).
11. Mikszta, J.A. et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 8, 415-419 (2002).
12. Widera, G. et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 24, 1653-1664 (2006).
13. Koutsonanos, D.G. et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One 4, e4773 (2009).
14. Zhu, Q. et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl. Acad. Sci. USA 106, 7968-7973 (2009).
15. Kim, Y.C. et al. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J. Infect. Dis. 201, 190-198 (2010).
16. Miyano, T. et al. Sugar micro needles as transdermic drug delivery system. Biomed. Microdevices 7, 185-188 (2005).
17. Ito, Y., Yoshimitsu, J., Shiroyama, K., Sugioka, N. & Takada, K. Self-dissolving microneedles for the percutaneous absorption of EPO in mice. J. Drug Target. 14, 255-261 (2006). (Pubitemid 44173291)
18. Lee, J.W., Park, J.H. & Prausnitz, M.R. Dissolving microneedles for transdermal drug delivery. Biomaterials 29, 2113-2124 (2008).
19. Sullivan, S.P., Murthy, N. & Prausnitz, M.R. Minimally invasive protein delivery with rapidly dissolving microneedles. Adv. Mater. 20, 933-938 (2008).
20. Robinson, B.V. PVP: A Critical Review of the Kinetics and Toxicology of Polyvinylpyrrolidone (Povidone). (Lewis Publishers, Chelsea, Michigan, 1990).
21. Park, J.-H., Allen, M.G. & Prausnitz, M.R. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J. Control. Release 104, 51-66 (2005).
22. Bronaugh, R.L., Stewart, R.F. & Congdon, E.R. Methods for in vitro percutaneous absorption studies II. Animal models for human skin. Toxicol. Appl. Pharmacol. 62, 481-488 (1982).
23. McGill, J. & Legge, K.L. Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J. Immunol. 183, 4177-4181 (2009).
24. Strengell, M., Sareneva, T., Foster, D., Julkunen, I. & Matikainen, S. IL-21 upregulates the expression of genes associated with innate immunity and TH1 response. J. Immunol. 169, 3600-3605 (2002).
25. Ozaki, K. et al. A critical role for IL-21 in regulating immunoglobulin production. Science 298, 1630-1634 (2002).
26. Zeng, R. et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201, 139-148 (2005).
27. Miller, M.A. & Pisani, E. The cost of unsafe injections. Bull. World Health Organ. 77, 808-811 (1999).
28. Mitragotri, S. Immunization without needles. Nat. Rev. Immunol. 5, 905-916 (2005).
29. Ravin, H.A., Seligman, A.M. & Fine, J. Polyvinyl pyrrolidone as a plasma expander; studies on its excretion, distribution and metabolism. N. Engl. J. Med. 247, 921-929 (1952).
30. Doherty, P.C. & Kelso, A. Toward a broadly protective influenza vaccine. J. Clin. Invest. 118, 3273-3275 (2008).
31. Katsikis, P.D., Schoenberger, S.P. & Pulendran, B. Probing the 'labyrinth' linking the innate and adaptive immune systems. Nat. Immunol. 8, 899-901 (2007).
32. Kupper, T.S. & Fuhlbrigge, R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4, 211-222 (2004).
33. Miller, L.S. & Modlin, R.L. Toll-like receptors in the skin. Semin. Immunopathol. 29, 15-26 (2007).
34. Skountzou, I., Quan, F.S., Jacob, J., Compans, R.W. & Kang, S.M. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24, 6110-6119 (2006).
35. Amorij, J.P. et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25, 6447-6457 (2007).
36. Compans, R.W. Hemagglutination-inhibition: rapid assay for neuraminic acidcontaining viruses. J. Virol. 14, 1307-1309 (1974).
37. Reed, L.J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27, 493-497 (1938).